When stem cell industry innovators from across the globe congregated in Miami at the end of January 2020 to discuss the current state and future expectations of the regenerative medicine industry, Biorasi had more than one reason to be excited about the event.
In Our Own Backyard
Biorasi has been looking forward to attending this year’s World Stem Cell Summit 2020 (WSCS 20) “in our own backyard,” and the event did not disappoint. Our on-site group included Jimmy El Hokayem, Ph.D., Associate Director of Program Development and Head of the Neurology and Regenerative Medicine Center of Excellence, as well as Ruslan Gorsky and Sofia Puerto from Biorasi’s Program Development Team.
“What we noticed this year was the number of small to mid-sized companies present, contributing to the regenerative medicine global dialogue,” said El Hokayem. “With so many key decision makers, the whole event was charged with excitement as we walked and talked to current colleagues and new friends on the exhibit floor and at panel discussions.”
Making the Connection
Sofia Puerto had the opportunity to meet with Matias Fernandez Viña, Medical Director at Stem Cell Therapy Argentina, who was presenting his studies on knee osteoarthritis. The team was also on-hand for a presentation by Matt Trudeau, VP at Bluebird Bio, on brand equity values in stem cell research.
In connecting with these and other stakeholders over the four-day event, we were impressed with the industry’s renewed emphasis on the patient – with sponsors, manufacturing, and support teams focusing on treatment reaching individuals in need. And in our role as CRO, we noted the unique challenges faced by these companies at each phase of the clinical trial, including:
- Planning – Relieving the logistical burden of each clinical trial phase
- Experience – Understanding the stem cell platform and devising a successful strategy
- Flexibility – Customizing solutions to meet specific tasks, with the ability to scale up or down
A Vital Industry
“Overall, our time spent at WSCS 20 showed positive results,” said Ruslan Gorsky. “The stem cell industry continues to remain vital as we and the rest of the world wait for the first stem cell treatment to be approved by the FDA.”
“The industry is moving in the right direction,” said El Hokayem. “Global innovators in stem cell and gene therapy are continuing to run clinical trials with novel approaches to research and treatment. There’s still work to do, however there is growth in the market, too. Each year, the science gets stronger and the knowledge base gets wider.”
Biorasi would like to thank the World Stem Cell Summit 2020 team for their hospitality during the event. We enjoyed connecting with everyone, and we can’t wait to see you again next year.
If you were unable to meet with us, but are interested in the role that an experienced CRO can play in the success of your upcoming clinical trials for regenerative medicine or other therapeutic areas, reach out to us for more information, we would love to connect!
